Provided by Tiger Trade Technology Pte. Ltd.

Precigen

7.60
+0.06000.80%
Post-market: 7.60-0.0031-0.04%19:44 EDT
Volume:3.83M
Turnover:28.94M
Market Cap:2.71B
PE:-7.10
High:7.64
Open:7.49
Low:7.40
Close:7.54
52wk High:8.98
52wk Low:2.99
Shares:356.51M
Float Shares:195.00M
Volume Ratio:0.63
T/O Rate:1.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0700
EPS(LYR):-1.3727
ROE:-837.08%
ROA:-18.14%
PB:62.18
PE(LYR):-5.54

Loading ...

Precigen, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Precigen Returns to Profit in Q2 FY26; Revenue Rises to $54.98 Million

Reuters
·
Aug 05

Precigen Posts Quarterly Profit as Papzimeos Sales Surge

Reuters
·
Aug 05

Precigen Q2 EPS $0.05 Beats $(0.01) Estimate, Sales $54.978M Beat $27.833M Estimate

Benzinga Earnings
·
Aug 05

Precigen, - Papzimeos Revenue Drives Company to Quarterly Profitability

THOMSON REUTERS
·
Aug 05

Precigen options imply 11.1% move in share price post-earnings

TIPRANKS
·
Aug 05

Precigen Price Target Maintained with a $14.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL)

TIPRANKS
·
Aug 03

Precigen CFO Harry Thomasian Jr Disposes of 100,000 Shares Worth $606,000

Reuters
·
Aug 01

Precigen Inc Expected to Post a Loss of 1 Cent a Share - Earnings Preview

Reuters
·
Aug 01

Earning Preview: Precigen Q2 revenue expected to increase by 4,074.98%, and institutional views are bullish

Earnings Agent
·
Jul 29

Precigen Schedules Q2 Financial Results Conference Call

Reuters
·
Jul 21

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

THOMSON REUTERS
·
Jul 21

Precigen CEO Helen Sabzevari Disposes of 346,836 Common Shares Worth $2,042,858.04

Reuters
·
Jul 02

Precigen Shareholders Approve 7 Million-share Increase to 2023 Incentive Plan at Annual Meeting

Reuters
·
Jun 25

Clearfield And 2 Insider Picks For Strong Growth

Simply Wall St.
·
Jun 24

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Simply Wall St.
·
Jun 21

Sector Update: Health Care

MT Newswires Live
·
Jun 15

Precigen Wins FDA Orphan Drug Exclusivity for Airway Disease Treatment

MT Newswires Live
·
Jun 15

Precigen reports PAPZIMEOS trial data show 83% complete responses sustained at least 36 months in RRP

Reuters
·
Jun 15